Faculty Profiles - TAKAHASHI, Yoshiyuki

Papers - TAKAHASHI, Yoshiyuki

Division display 181 - 200 of about 517 ／ All the affair displays >>

A Case of FOXN1-SCID Identified by TREC/KREC Newborn Screening Program

Wakamatsu, M; Kojima, D; Muramatsu, H; Okuno, Y; Kataoka, S; Nakamura, T; Sakai, Y; Nakajima, Y; Ito, T; Takahashi, Y

PEDIATRIC BLOOD & CANCER Vol. 68 2021.11

A Case of Severe Combined Immunodeficiency found in Newborn Screening for Primary Immunodeficiency in Aichi Prefecture

Yamashita, D; Wakamatsu, M; Muramatsu, H; Kojima, D; Kataoka, S; Okuno, Y; Nakamura, F; Sakai, Y; Ito, T; Takahashi, Y

PEDIATRIC BLOOD & CANCER Vol. 68 2021.11

Cartilage-Hair Hypoplasia Diagnosed after Optional Screening of Neonates for Severe Combined Immunodeficiency

Tsumura, Y; Wakamatsu, M; Muramatsu, H; Okuno, Y; Nakajima, Y; Ito, T; Nakamura, T; Sakai, Y; Kojima, S; Takahashi, Y

PEDIATRIC BLOOD & CANCER Vol. 68 2021.11

Clinical Characteristics and Outcomes of Acute Megakaryoblastic Leukemia with T(1;22)(P13;Q13) in Children

Hama, A; Nagai, K; Hasegawa, D; Hasegawa, D; Shimada, A; Takahashi, Y; Taga, T; Adachi, S; Tomizawa, D

PEDIATRIC BLOOD & CANCER Vol. 68 2021.11

A Case of Fanct without Abnormality in the Peripheral Blood Chromosome Breakage Test

Nishi, M; Eguchi, H; Muramatsu, H; Takahashi, Y; Matsuo, M

PEDIATRIC BLOOD & CANCER Vol. 68 2021.11

Hematopoietic Cell Transplantation for Severe Combined Immunodeficiency Patients: a Japanese Retrospective Study. International journal Open Access

Satoshi Miyamoto, Katsutsugu Umeda, Mio Kurata, Akira Nishimura, Masakatsu Yanagimachi, Masataka Ishimura, Maho Sato, Tomonari Shigemura, Motohiro Kato, Yoji Sasahara, Akihiro Iguchi, Takashi Koike, Yoshiyuki Takahashi, Michiko Kajiwara, Masami Inoue, Yoshiko Hashii, Hiromasa Yabe, Koji Kato, Yoshiko Atsuta, Kohsuke Imai, Tomohiro Morio

Journal of clinical immunology Vol. 41 ( 8 ) page： 1865 - 1877 2021.11

Language：English Publishing type：Research paper (scientific journal)

PURPOSE: Hematopoietic cell transplantation (HCT) is a curative therapy for patients with severe combined immunodeficiency (SCID). Here, we conducted a nationwide study to assess the outcome of SCID patients after HCT in Japan. METHODS: A cohort of 181 SCID patients undergoing their first allogeneic HCT in 1974-2016 was studied by using the Japanese national database (Transplant Registry Unified Management Program, TRUMP). RESULTS: The 10-year overall survival (OS) of the patients who received HCT in 2006-2016 was 67%. Umbilical cord blood (UCB) transplantation was performed in 81 patients (45%). The outcomes of HCT from HLA-matched UCB (n = 21) and matched sibling donors (n = 22) were comparable, including 10-year OS (91% vs. 91%), neutrophil recovery (cumulative incidence at 30 days, 89% vs. 100%), and platelet recovery (cumulative incidence at 60 days, 89% vs. 100%). Multivariate analysis of the patients who received HCT in 2006-2016 demonstrated that the following factors were associated with poor OS: bacterial or fungal infection at HCT (hazard ratio (HR): 3.8, P = 0.006), cytomegalovirus infection prior to HCT (HR: 9.4, P = 0.03), ≥ 4 months of age at HCT (HR: 25.5, P = 0.009), and mismatched UCB (HR: 19.8, P = 0.01). CONCLUSION: We showed the potential of HLA-matched UCB as a donor source with higher priority for SCID patients. We also demonstrated that early age at HCT without active infection is critical for a better prognosis, highlighting the importance of newborn screening for SCID.

DOI： 10.1007/s10875-021-01112-5

Web of Science

PubMed

Urinary Biomarkers Predicting Treatment Outcomes in Neuroblastoma

Atsushi Narita, Akinari Hinoki, Kazuki Yokota, Motoharu Hamada, Shinsuke Kataoka, Nozomu Kawashima, Hideki Muramatsu, Nobuhiro Nishio, Hiroo Uchida, Yoshiyuki Takahashi

PEDIATRIC BLOOD & CANCER Vol. 68 2021.11

Using Chemotherapy to Treat Neuroblastoma Stage 4S with Hepatomegaly in a Patient Younger than 2 Months Old

Masayuki Imaya, Nobuhiro Nishio, Rieko Taniguchi, Shinsuke Kataoka, Motoharu Hamada, Eri Nishikawa, Nozomu Kawashima, Atsushi Narita, Hideki Muramatsu, Yoshiyuki Takahashi

PEDIATRIC BLOOD & CANCER Vol. 68 2021.11

Next-Generation Sequencing to Detect Pathogens in Pediatric Febrile Neutropenia: A Single-Center Retrospective Study of 112 Cases Open Access

Kazuhiro Horiba, Yuka Torii, Toshihiko Okumura, Suguru Takeuchi, Takako Suzuki, Jun-ichi Kawada, Hideki Muramatsu, Yoshiyuki Takahashi, Tomoo Ogi, Yoshinori Ito

Open Forum Infectious Diseases Vol. 8 ( 11 ) page： ofab223 2021.11

Language：English Publishing type：Research paper (scientific journal) Publisher：Oxford University Press (OUP)

<title>Abstract</title>
<sec>
<title>Background</title>
Febrile neutropenia (FN) is a frequent complication in immunocompromised patients. However, causative microorganisms are detected in only 10% of patients. This study aimed to detect the microorganisms that cause FN using next-generation sequencing (NGS) to idenjpgy the genome derived from pathogenic microorganisms in the bloodstream. Here, we implemented a metagenomic approach to comprehensively analyze microorganisms present in clinical samples from patients with FN.

</sec>
<sec>
<title>Methods</title>
FN is defined as 1) a neutrophil count &lt; 500/µL, and 2) fever ≥ 37.5 °C. Plasma/serum samples of 112 pediatric patients with FN, 10 patients with neutropenia without fever (NE), were sequenced by NGS and analyzed by a metagenomic pipeline PATHDET.

</sec>
<sec>
<title>Results</title>
The putative pathogens were detected by NGS in 5 of 10 patients with FN with positive for blood culture results, 15 of 87 patients (17%) with negative for blood culture results, and 3 of 8 patients with NE. Several bacteria that were common in the oral, skin, and gut flora were commonly detected in blood samples, suggesting translocation of the human microbiota to the bloodstream in the setting of neutropenia. The cluster analysis of the microbiota in blood samples using NGS demonstrated that the representative bacteria of each cluster was mostly consistent with the pathogens in each patient.

</sec>
<sec>
<title>Conclusions</title>
NGS technique has a great potential for detecting causative pathogens in patients with FN. Cluster analysis, which extracts characteristic microorganisms from a complex microbial population, may be effective to detect pathogens in minute quantities of microbiota, such as those from the bloodstream.

</sec>

DOI： 10.1093/ofid/ofab223

Open Access

Web of Science

PubMed

RE-Treatment with CD19-Targeted CAR-T Cells for Relapse after CD19-CAR-T Cell Therapy

Nobuhiro Nishio, Motoharu Hamada, Eri Nishikawa, Nozomu Kawashima, Atsushi Narita, Hideki Muramatsu, Kai Wang, Huyong Zheng, Jung-Li Chang, Yoshiyuki Takahashi

PEDIATRIC BLOOD & CANCER Vol. 68 2021.11

Prolonged Hospitalization and Late Gastroenterological Complications in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Nozomu Kawashima, Shinsuke Kataoka, Motoharu Hamada, Eri Nishikawa, Rieko Taniguchi, Atsushi Narita, Hideki Muramatsu, Nobuhiro Nishio, Yoshiyuki Takahashi

PEDIATRIC BLOOD & CANCER Vol. 68 2021.11

Outcomes of KIR-Ligand Incompatible Allogeneic Cord Blood Transplantation for Relapsed Stage 4 Neuroblastoma: A Single Institutional Study

Shinsuke Kataoka, Nobuhiro Nishio, Manabu Wakamatsu, Rieko Taniguchi, Eri Nishikawa, Motoharu Hamada, Nozomu Kawashima, Atsushi Narita, Hideki Muramatsu, Yoshiyuki Takahashi

PEDIATRIC BLOOD & CANCER Vol. 68 2021.11

Strategy of Intensified Therapy for High Risk Pediatric Acute Lymphoblastic Leukemia Based on NGS-MRD-Based Risk Stratification

Motoharu Hamada, Masayuki Imaya, Yusuke Okuno, Nozomu Kawashima, Rieko Taniguchi, Atsushi Narita, Hideki Muramatsu, Nobuhiro Nishio, Shinji Hasegawa, Yoshiyuki Takahashi

PEDIATRIC BLOOD & CANCER Vol. 68 2021.11

Ten Patients with RUNX1 Mutation who were Suspected with FPD-MM in a Pediatric Cohort of Inherited Bone Marrow Failure Syndrome

Ayako Yamamori, Motoharu Hamada, Hideki Muramatsu, Rieko Taniguchi, Shinsuke Kataoka, Nozomu Kawashima, Atsushi Narita, Nobuhiro Nishio, Yusuke Okuno, Yoshiyuki Takahashi

PEDIATRIC BLOOD & CANCER Vol. 68 2021.11

Successful Therapy with Ascites Drainage and Defibrotide for Veno-Occlusive Disease Developed after Bone Marrow Transplantation in Acute Lymphoblastic Leukemia

Ryo Maemura, Atsushi Narita, Shinsuke Kataoka, Rieko Taniguchi, Motoharu Hamada, Eri Nishikawa, Nozomu Kawashima, Nobuhiro Nishio, Hideki Muramatsu, Yoshiyuki Takahashi

PEDIATRIC BLOOD & CANCER Vol. 68 2021.11

がん遺伝子パネル検査でBRAF V600E変異を認めた副腎腫瘍の16歳女性

佐治木大知, 村松秀城, 津村悠介, 前村遼, 今屋雅之, 山森彩子, 若松学, 吉田太郎, 三輪田俊介, 成田幸太郎, 市川大輔, 濱田太立, 谷口理恵子, 鈴木喬悟, 川島希, 西川英里, 成田敦, 西尾信博, 高橋義行, 島田聡子, 榊原綾子, 下山芳江, 岩淵英人

日本小児血液・がん学会雑誌 Vol. 58 ( 3 ) page： 325 - 326 2021.11

Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene-rearranged acute lymphoblastic leukemia. International journal Open Access

Takayuki Takachi, Tomoyuki Watanabe, Takako Miyamura, Akiko Moriya Saito, Takao Deguchi, Toshinori Hori, Tomomi Yamada, Shigeru Ohmori, Masami Haba, Yuki Aoki, Sae Ishimaru, Shinya Sasaki, Junjiro Ohshima, Akihiro Iguchi, Yoshiyuki Takahashi, Nobuyuki Hyakuna, Atsushi Manabe, Keizo Horibe, Eiichi Ishii, Katsuyoshi Koh, Daisuke Tomizawa

Blood advances Vol. 5 ( 19 ) page： 3891 - 3899 2021.10

Language：English Publishing type：Research paper (scientific journal)

The role of allogeneic hematopoietic stem cell transplantation (HSCT) for infants with acute lymphoblastic leukemia (ALL) and KMT2A gene rearrangement (KMT2A-r) is controversial in terms of both its efficacy and potential for acute and late toxicities. In Japanese Pediatric Leukemia/Lymphoma Study Group trial MLL-10, by introducing intensive chemotherapy, indication of HSCT was restricted to patients with high-risk (HR) features only (KMT2A-r and either age <180 days or presence of central nervous system leukemia). Of the 56 HR patients, 49 achieved complete remission. Forty-three patients received HSCT in first remission including 38 patients receiving protocol-specified HSCT with conditioning consisting of individualized targeted doses of busulfan, etoposide, and cyclophosphamide. Three-year event-free survival (EFS) of 56.8% (95% confidence interval [CI], 42.4% to 68.8%) and overall survival of 80.2% (95% CI, 67.1% to 88.5%) were accomplished. Univariable analysis showed that Interfant-HR criteria and flow cytometric minimal residual disease (MRD; ≥0.01%), both at the end of induction and at the end of consolidation (EOC), were significantly associated with poorer EFS. In the multivariable analysis, positive MRD at EOC was solely associated with poor EFS (P < .001). Rapid pretransplant MRD clearance and tailored HSCT strategy in the MLL-10 trial resulted in a favorable outcome for infants with HR KMT2A-r ALL. However, considering the high rate of potentially life-threatening toxicities and the risk of late effects, its indication should be further restricted or even eliminated in the future by introducing more effective therapeutic modalities with minimal toxicities. This trial was registered at the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) as #UMIN000004801.

DOI： 10.1182/bloodadvances.2020004157

Open Access

Web of Science

PubMed

Single-Arm Non-Blinded Multicenter Clinical Trial on T-Cell-Replete Haploidentical Stem Cell Transplantation Using Low-Dose Antithymocyte Globulin for Relapsed and Refractory Pediatric Acute Leukemia.

Kada A, Kikuta A, Saito AM, Kato K, Iguchi A, Yabe H, Ishida H, Hyakuna N, Takahashi Y, Nagasawa M, Hashii Y, Umeda K, Matsumoto K, Fujisaki H, Yano M, Nakazawa Y, Sano H

The Kurume medical journal Vol. 66 ( 3 ) page： 161 - 168 2021.10

Clinical Images: Extensive multiple organ involvement in VEXAS syndrome Open Access

Takahashi, N; Takeichi, T; Nishida, T; Sato, J; Takahashi, Y; Yamamura, M; Ogi, T; Akiyama, M

ARTHRITIS & RHEUMATOLOGY Vol. 73 ( 10 ) page： 1896 - 1897 2021.10

Acquisition of a rare NUP98-BPTF fusion gene associated with recurrence of acute myeloid leukemia. International journal

Koji Kawaguchi, Shohei Azumi, Yosuke Itakura, Takayuki Takachi, Taemi Ogura, Yasuo Horikoshi, Kyogo Suzuki, Hideki Muramatsu, Asahito Hama, Yoshiyuki Takahashi, Kenichiro Watanabe

Pediatric blood & cancer Vol. 68 ( 10 ) page： e29201 2021.10

　 PREV - NEXT 　

<TAKAHASHI, Yoshiyuki>

Papers - TAKAHASHI, Yoshiyuki